Fernwood Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Fernwood Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32,259	Closed	-$59.7K	–	197
2023 Q1	$59.7K	Hold	32,259	–	–	0.02%	180
2022 Q4	$35.8K	Hold	32,259	–	–	0.01%	178
2022 Q3	$75K	Hold	32,259	–	–	0.03%	179
2022 Q2	$98K	Hold	32,259	–	–	0.04%	176
2022 Q1	$219K	Buy	32,259 +5,677	+21%	+$40.5K	0.08%	180
2021 Q4	$222K	Sell	26,582 -102	-0.4%	-$840	0.07%	191
2021 Q3	$198K	Buy	26,684 +7,463	+39%	+$46.2K	0.07%	194
2021 Q2	$131K	Buy	19,221 +6,377	+50%	+$53K	0.04%	195
2021 Q1	$132K	Buy	+12,844	New	+$141K	0.05%	186

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fernwood Investment Management's JNCE Position: Q2 2023 in Review

Fernwood Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 32,259 shares — an estimated $59.7K sold.

Fernwood Investment Management first reported a position in JNCE in Q1 2021 and held it in 9 quarters. The position peaked at $222K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Fernwood Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fernwood Investment Management sold 32,259 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $59.7K.
Fernwood Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Fernwood Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $222K in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Fernwood Investment Management's 13F filing for Q2 2023, filed 9 Aug 2023.